This article is more than 5 years old. Information may no longer be current.
AGTC announces enrollment milestones in two gene therapy trials
Click Here to Manage Email Alerts
Applied Genetic Technologies Corporation has completed enrollment in two phase 1/2 clinical trials of adeno-associated virus-based gene therapies, according to a press release.
One trial evaluating a product candidate for achromatopsia caused by mutations in the CNGB3 gene has completed its dose escalation portion enrollment, while a trial for an X-linked retinitis pigmentosa treatment candidate caused by mutations in the RPGR gene has completed expansion group enrollment.
“Continued success enrolling in all our clinical trials is critical to advancing new and innovative gene therapies for patients with inherited retinal diseases that lack approved treatment options, and we are pleased with the progress we have made,” Sue Washer, president and CEO of AGTC, said in the release. “Achieving these important milestones is a testament to the dedication of the AGTC clinical teams and our clinical investigators, underscoring the support that our investigational therapies have among the patient communities we seek to serve.”
Both trials are assessing the safety of the vector and subretinal delivery procedure of the treatment candidates, the release said.
Two phase 1/2 trials for achromatopsia are underway, evaluating the two most common genes, CNGB3 and CNGA3. Twelve patients are enrolled in the CNGB3 trial and six in the CNGA3 trial.
The dose escalation portion of the X-linked retinitis pigmentosa trial has enrolled 10 patients, with six patients in the expansion portion.